Program
KRAS G12D Inhibitor VS-7375
Also written as “GFH375”, “VS-7375” and “GFH375 + Cetuximab”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Pancreatic Neoplasms · Colorectal Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Genfleet Therapeutics (Shanghai) | 87 open or running | phase 3since Nov 20, 2025 | Jul 8, 2024 | Apr 30, 2027phase 2 · NCT07554859 |
| Verastem | 44 open or running | phase 2since May 26, 2025 | May 26, 2025 | Jun 2027phase 2 · NCT07659782 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 8, 2024First study: phase 2 study in KRAS G12D MutationsNew to Genfleet Therapeutics (Shanghai)Genfleet Therapeutics (Shanghai) · NCT06500676 · 407 planned · China
- May 26, 2025Verastem’s first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to VerastemVerastem · NCT07020221 · 616 planned · United States, Australia, France and more
- Jun 3, 2025Phase 2 study in Pancreatic NeoplasmsGenfleet Therapeutics (Shanghai) · NCT07026916
- Nov 14, 2025Phase 2 study in Colorectal NeoplasmsGenfleet Therapeutics (Shanghai) · NCT07259590 · 126 planned · China
- Nov 20, 2025Phase 3 study in Pancreatic NeoplasmsPhase 3 reachedGenfleet Therapeutics (Shanghai) · NCT07262567 · 320 planned · China
- Apr 21, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungGenfleet Therapeutics (Shanghai) · NCT07554859 · 90 planned · China
- May 26, 2026Phase 2 study in Pancreatic NeoplasmsVerastem · NCT07644559 · 185 planned · United States, Australia, Canada and more
- Jun 15, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungGenfleet Therapeutics (Shanghai) · NCT07668752 · 300 planned · China
- Jun 15, 20262 phase 2 studiesVerastem · NCT07659795, NCT07659782
- Aug 10, 2026Phase 2 study in Pancreatic NeoplasmsGenfleet Therapeutics (Shanghai) · NCT07784374 · 120 planned · China
- Oct 18, 2026Phase 3 study in Colorectal NeoplasmsGenfleet Therapeutics (Shanghai) · NCT07913360 · 368 planned
Ahead
- Apr 30, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungGenfleet Therapeutics (Shanghai) · NCT07554859
- Jun 2027Primary completion: phase 2 study in Colorectal NeoplasmsVerastem · NCT07659795
- Jun 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungVerastem · NCT07659782
- Jun 2027Primary completion: phase 2 study in Pancreatic NeoplasmsVerastem · NCT07644559
TargetBeta
“An orally bioavailable non-covalent small molecule inhibitor of both the active, guanosine triphosphate (GTP)-bound form and the inactive, guanosine diphosphate (GDP)-bound form of the oncogenic KRAS substitution mutation G12D, ”NCIt, by rule
Other programs on KRAS
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sotorasibrule | Amgen | phase 3 | 28 |
| adagrasibrule | Bristol-Myers Squibb | phase 3 | 16 |
| olomorasib | Eli Lilly | phase 3 | 16 |
| divarasib | Hoffmann-La Roche | phase 3 | 13 |
| glecirasibrule | Allist Pharmaceuticals | phase 3 | 12 |
| calderasib | Merck | phase 3 | 12 |
| daraxonrasibrule | Revolution Medicines | phase 3 | 10 |
| garsorasibrule | InventisBio | phase 3 | 8 |
| KRAS G12D Inhibitor HRS-4642 | Jiangsu HengRui Medicine | phase 3 | 7 |
| zoldonrasibrule | Revolution Medicines | phase 3 | 6 |
| HRS-7058 | Jiangsu HengRui Medicine | phase 3 | 6 |
| opnurasibrule | Novartis | phase 3 | 5 |
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07913360Colorectal Neoplasms | 3 | Not yet recruiting | Genfleet Therapeutics (Shanghai) | Nov 2028 | 368 |
| NCT07784374Pancreatic Neoplasms · China | 2 | Recruiting | Genfleet Therapeutics (Shanghai) | Aug 31, 2028 | 120 |
| NCT07668752Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | Genfleet Therapeutics (Shanghai) | Jun 30, 2030 | 300 |
| NCT07659795Colorectal Neoplasms · United States, Australia, France and more | 2 | Recruiting | Verastem | Jun 2027 | 150 |
| NCT07659782Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more | 2 | Recruiting | Verastem | Jun 2027 | 105 |
| NCT07644559Pancreatic Neoplasms · United States, Australia, Canada and more | 2 | Recruiting | Verastem | Jun 2027 | 185 |
| NCT07554859Carcinoma, Non-Small-Cell Lung · China | 2 | Not yet recruiting | Genfleet Therapeutics (Shanghai) | Apr 30, 2027 | 90 |
| NCT07262567Pancreatic Neoplasms · China | 3 | Recruiting | Genfleet Therapeutics (Shanghai) | Jun 2027 | 320 |
| NCT07259590Colorectal Neoplasms · China | 2 | Recruiting | Genfleet Therapeutics (Shanghai) | Jul 2027 | 126 |
| NCT07026916Pancreatic Neoplasms | 2 | Withdrawn | Genfleet Therapeutics (Shanghai) | Aug 2027 | 0 |
| NCT07020221Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more | 2 | Recruiting | Verastem | Dec 2028 | 616 |
| NCT06500676KRAS G12D Mutations · China | 2 | Recruiting | Genfleet Therapeutics (Shanghai) | Jul 31, 2028 | 407 |
How it is read
Names in the registry
- “GFH375”, 7 entries
- “VS-7375”, 4 entries
- “GFH375 + Cetuximab”, 1 entry
- “ArmA:GFH375”, 1 entry
- “Arm B:GFH375”, 1 entry
Codes read as this program: GFH375.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Pancreatic Neoplasms, 4 studies
- Colorectal Neoplasms, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.